Table 5.
Comparison of demographic features, clinical characteristics, laboratory tests, metabolic syndrome components together with VASI and VIDA scores between the segmental and non-segmental vitiligo patients
| Variables | Non-segmental vitiligo patients (n = 144) |
Segmental vitiligo patients (n = 11) |
p-Value |
|---|---|---|---|
| Gender (n, %) | 0.730 | ||
| Male | 78 (54.2%) | 5 (45.5%) | |
| Female | 66 (45.8) | 6 (54.5%) | |
| Age (mean ± SD, range) (years) | 37.06 ± 12.10 (18–69) | 37.01 ± 12.20 (18–69) | 0.910 |
| Frequency of risk factors for metabolic syndrome, n (%) | |||
| Diabetes mellitus | 5 (3.4%) | 0 (0%) | 0.69 |
| Hashimoto’s thyroiditis | 26 (18.1%) | 1 (9.1%) | 0.39 |
| Hypertension | 49 (34%) | 4 (36.4%) | 0.55 |
| Hyperlipidemia | 84 (58.3%) | 5 (45.5%) | 0.30 |
| Obesity | 36 (25%) | 1 (9.1%) | 0.67 |
| Smoking | 57 (39.6%) | 2 (18.2%) | 0.20 |
| Alcohol consumption | 45 (31.3%) | 5 (45.5%) | 0.33 |
| FPG (mg/dL) (mean ± SD) | 93.4 ± 1.79 | 88.18 ± 1.80 | 0.42 |
| HDL cholesterol (mg/dL) (mean ± SD) | 50.01 ± 0.91 | 50.73 ± 3.5 | 0.83 |
| LDL cholesterol (mg/dL) (mean ± SD) | 134.97 ± 3.32 | 124.25 ± 10.09 | 0.35 |
| TG (mg/dL) (mean ± SD) | 127.88 ± 6.21 | 119.09 ± 28.69 | 0.71 |
| CRP (mg/L)(mean ± SD) | 0.37 ± 0.02 | 0.24 ± 0.02 | 0.001 |
| Vitamin B12 (pg/mL) (mean ± SD) | 244.86 ± 8.67 | 248.45 ± 23.70 | 0.91 |
| Vitamin B12 deficiency rate, n (%) | 53 (36.8%) | 4 (36.4%) | 0.62 |
| Vitamin B12 replacement rate, n (%) | 31 (21.5%) | 1 (9.1%) | 0.46 |
| Waist circumference (cm) (mean ± SD) | 95.79 ± 1.02 | 82.09 ± 2.70 | <0.001 |
| BMI (kg/m2) (mean ± SD) | 26.62 ± 0.39 | 21.90 ± .66 | 0.001 |
| Systolic blood pressure (mmHg) (mean ± SD) | 115.90 ± 1.2 | 114.09 ± 5.9 | 0.71 |
| Diastolic blood pressure (mmHg) (mean ± SD) | 75.00 ± 0.83 | 72.72 ± 3.25 | 0.47 |
| Metabolic syndrome rate, n (%) | |||
| NCEP-ATPIII criteria | 57 (39.6%) | 1 (9.1%) | 0.05 |
| IDF criteria | 60 (41.7%) | 2 (18.2%) | 0.20 |
| VASI Groups, n (%) | <0.001 | ||
| Group 1 (<1.94) | 40 (27.8%) | 11 (100%) | |
| Group 2 (1.94–6.89) | 51 (35.4%) | 0 (0%) | |
| Group 3 (> 6.89) | 53 (36.8%) | 0 (0%) | |
| VIDA Groups, n (%) | <0.001 | ||
| Group A (−1–0) | 19 (13.2%) | 6 (54.5%) | |
| Group B (1–2) | 35 (24.3%) | 3 (27.3%) | |
| Group C (3–4) | 90 (62.5%) | 2 (18.2%) | |
FPG, Fasting Plasma Glucose; HDL, High-Density Lipoprotein; LDL, Low-Density Lipoprotein; TG, Triglyceride; CRP, C-Reactive Protein; BMI, Body-Mass Index; NCEP-ATPIII, National Cholesterol Education Program Adult Treatment Panel III; IDF, The International Diabetes Federation; NCEP-ATPIII, National Cholesterol Education Program Adult Treatment Panel III; IDF, The International Diabetes Federation; VASI, Vitiligo Area Severity Index; VIDA, Vitiligo Disease Activity Score.